Sustained Modeling-Based Bone Formation during Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains with Denosumab

Journal of Bone and Mineral Research

Volumn 30, Issue 7, 2015, Pages 1280-1289

  Ominsky, Michael S ^a   Libanati, Cesar ^a   Niu, Qing Tian ^a   Boyce, Rogely W ^a   Kostenuik, Paul J ^a   Wagman, Rachel B ^a   Baron, Roland ^b,c   Dempster, David W ^d,e  

^a AMGEN INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^d New York Presbyterian Columbia University Medical Center   (United States)

^e HELEN HAYES HOSPITAL   (United States)

Author keywords

ANTIRESORPTIVES; BONE HISTOMORPHOMETRY; BONE MODELING AND REMODELING; OSTEOPOROSIS; PRECLINICAL STUDIES

Indexed keywords

DENOSUMAB; FLUORESCENT DYE;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE REMODELING; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRAGILITY FRACTURE; HISTOLOGY; MACACA FASCICULARIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; TRABECULAR BONE; TREATMENT DURATION; AGING; ANIMAL; BONE DEVELOPMENT; DRUG EFFECTS; FEMORAL NECK; METABOLISM; PHYSIOLOGY; STAINING;

AGING; ANIMALS; BONE DENSITY; BONE REMODELING; DENOSUMAB; FEMALE; FEMUR NECK; FLUORESCENT DYES; MACACA FASCICULARIS; OSTEOGENESIS; OVARIECTOMY; STAINING AND LABELING;

EID: 84930680391     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2480     Document Type: Article

References (38)

1. Cummings SR, San MJ, McClung MR, et al., Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-65.
2. Papapoulos S, Lippuner K, Roux C, Hall J., Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension. J Bone Miner Res. 2013; 28 Suppl 1:LB-MO26.
3. Riggs BL, Parfitt AM,. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res. 2005; 20: 177-84.
4. Boivin G, Meunier PJ,. Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact. 2002; 2: 538-43.
5. Seeman E, Libanati C, Austin M, et al., The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy. J Bone Miner Res. 2011; 26 Suppl 1: 1064.
6. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS,. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone. 2011; 49: 151-61.
7. Frost HM,. Wolff's Law and bone's structural adaptations to mechanical usage: an overview for clinicians. Angle Orthod. 1994; 64: 175-88.
8. Russo CR, Lauretani F, Seeman E, et al., Structural adaptations to bone loss in aging men and women. Bone. 2006; 38: 112-8.
9. Ruff CB, Hayes WC,. Subperiosteal expansion and cortical remodeling of the human femur and tibia with aging. Science. 1982; 217: 945-8.
10. Kontulainen S, Sievanen H, Kannus P, Pasanen M, Vuori I., Effect of long-term impact-loading on mass, size, and estimated strength of humerus and radius of female racquet-sports players: a peripheral quantitative computed tomography study between young and old starters and controls. J Bone Miner Res. 2002; 17: 2281-9.
11. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK,. Bone loss and bone size after menopause. N Engl J Med. 2003; 349: 327-34.
12. Gerstenfeld LC, Sacks DJ, Pelis M, et al., Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009; 24: 196-208.
13. Schett G, Stolina M, Dwyer D, et al., Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum. 2009; 60: 2644-54.
14. National Research Council. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, DC: The National Academies Press; 2011.
15. Ominsky MS, Stouch B, Schroeder J, et al., Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 2011; 49: 162-73.
16. Hattner R, Epker BN, Frost HM,. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature. 1965; 206: 489-90.
17. Garn SM,. The earlier gain and the later loss of cortical bone, in nutritional perspective. Springfield, IL: Charles C Thomas; 1970.
18. Epker BN, Frost HM,. Periosteal appositional bone growth from age two to age seventy in man. A tetracycline evaluation. Anat Rec. 1966; 154: 573-7.
19. Nawathe S, Nguyen B, Akhlaghpour H, Barzanian N, Bouxsein ML, Keaveny TM,. Cortical-trabecular load sharing in the human femoral neck. Trans ORS. 2014; 39: 1515.
20. Jerome CP, Peterson PE,. Nonhuman primate models in skeletal research. Bone. 2001; 29: 1-6.
21. Riggs BL, Melton LJ III, Robb RA, et al., Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res. 2004; 19: 1945-54.
22. Shahnazari M, Dwyer D, Chu V, et al., Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone. 2012; 50: 628-37.
23. Pietschmann P, Skalicky M, Kneissel M, et al., Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp Gerontol. 2007; 42: 1099-108.
24. Pennypacker BL, Chen CM, Zheng H, et al., Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys. J Bone Miner Res. 2014; 29: 1847-58.
25. Lindsay R, Cosman F, Zhou H, et al., A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res. 2006; 21: 366-73.
26. Cosman F, Dempster DW, Nieves J, et al., Bone remodeling and structure in the proximal femur. J Bone Miner Res. 2013; 28 Suppl 1: SA0371.
27. Zebaze RM, Libanati C, Austin M, et al., Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014; 59: 173-9.
28. Poole K, Treece GM, Gee A, et al., Denosumab treatment is associated with progressive improvements in cortical mass and thickness throughout the hip. J Bone Miner Res. 2013; 28 Suppl 1: 1133.
29. Zebaze R, Libanati C, McClung MR, et al., Denosumab reduces hip cortical porosity in women with osteoporosis. J Bone Miner Res. 2013; 28 Suppl 1: 1065.
30. Epker BN, Frost HM,. A histological study of remodeling at the periosteal, haversian canal, cortical endosteal, and trabecular endosteal surfaces in human rib. Anat Rec. 1965; 152: 129-35.
31. Bliziotes M, Sibonga JD, Turner RT, Orwoll E., Periosteal remodeling at the femoral neck in nonhuman primates. J Bone Miner Res. 2006; 21: 1060-7.
32. Tribble MB, Cohen A, de Bakker CM, Nishiyama K, Shane E, Liu XS,. Increased endocortical formation and periosteal resorption in premenopausal women with idiopathic osteoporosis treated with intermittent parathyroid hormone. Trans ORS. 2014; 60: 2006.
33. Boyce RW, Varela A, Chouinard L, et al., Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period. Bone. 2014; 64: 314-25.
34. Misof B, Roschger P, Ominsky M, Messmer P, Kostenuik P, Klaushofer K., The effect of denosumab on the bone matrix mineralization in mice. J Bone Miner Res. 2011; 26 Suppl 1: FR0058.
35. Borah B, Dufresne TE, Ritman EL, et al., Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone. 2006; 39: 345-52.
36. Boskey AL, Spevak L, Weinstein RS,. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int. 2009; 20: 793-800.
37. Gamsjaeger S, Buchinger B, Zwettler E, et al., Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. J Bone Miner Res. 2011; 26: 12-8.
38. Misof BM, Roschger P, Gabriel D, et al., Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort. J Bone Miner Res. 2013; 28: 442-8.